Home
Shukra Pharmaceuticals Ltd PE Ratio

Shukra Pharmaceuticals Ltd
NSE: SHUKRAPHARMA
PE
Key Highlights
- The P/E Ratio of Shukra Pharmaceuticals Ltd is 103.5 as of 22 Feb 11:50 AM .
- The P/E Ratio of Shukra Pharmaceuticals Ltd changed from 203.3 on March 2020 to 19.3 on March 2024 . This represents a CAGR of -37.56% over 5 years.
- The Latest Trading Price of Shukra Pharmaceuticals Ltd is ₹ 193.55 as of 21 Feb 15:30 .
- The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
- The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.
Historical P/E Ratio of Shukra Pharmaceuticals Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Shukra Pharmaceuticals Ltd
Company Fundamentals for Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd
NSE: SHUKRAPHARMA
Share Price
Market Price of Shukra Pharmaceuticals Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
21 Feb 2025 | 193.55 |
20 Feb 2025 | 197.5 |
19 Feb 2025 | 201.5 |
18 Feb 2025 | 205.6 |
17 Feb 2025 | 202.55 |
14 Feb 2025 | 206.65 |
13 Feb 2025 | 210.85 |
12 Feb 2025 | 215.15 |
11 Feb 2025 | 219.5 |
10 Feb 2025 | 215.3 |
SWOT Analysis Of Shukra Pharmaceuticals Ltd
BlinkX Score for Shukra Pharmaceuticals Ltd
Asset Value vs Market Value of Shukra Pharmaceuticals Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of P/E Ratio
Company | Market Cap | PE Ratio |
---|
Shukra Pharmaceuticals Ltd | 847.52 | 103.5 |
Sun Pharmaceuticals Industries Ltd | 394223 | 33.4 |
Divis Laboratories Ltd | 152610 | 73.8 |
Cipla Ltd | 119067 | 23.9 |
Torrent Pharmaceuticals Ltd | 102739 | 55.2 |
Dr Reddys Laboratories Ltd | 96124 | 17.9 |
Company | |
---|---|
Shukra Pharmaceuticals Ltd | 847.52 |
Sun Pharmaceuticals Industries Ltd | 394223 |
Divis Laboratories Ltd | 152610 |
Cipla Ltd | 119067 |
Torrent Pharmaceuticals Ltd | 102739 |
Dr Reddys Laboratories Ltd | 96124 |
PE Ratio of Shukra Pharmaceuticals Ltd Explained
₹847.52
Market cap
₹8
Earnings
103.5X
PE Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E Ratio Formula
P/E ratio = (CMP of share/ Earning per share)
Types of Price to Earning Ratio
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
PE Ratio of Pharmaceuticals Industry over time
PE Ratio of Top Sectors
Historical Market Cap of Shukra Pharmaceuticals Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Shukra Pharmaceuticals Ltd
Historical Revenue, EBITDA and Net Profit of Shukra Pharmaceuticals Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Revenue, EBITDA and Net Profit of Shukra Pharmaceuticals Ltd
Revenue
EBITDA
Net Profit
Historical Dividend Payout of Shukra Pharmaceuticals Ltd
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Historical Dividend Payout of Shukra Pharmaceuticals Ltd
About Shukra Pharmaceuticals Ltd
- Shukra Pharmaceuticals Limited (Formerly known Relish Pharmaceuticals Limited) was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
- The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
- Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.
Shukra Pharmaceuticals Ltd News Hub
Shukra Pharmaceuticals standalone net profit rises 16.67% in the June 2024 quarter
Net profit of Shukra Pharmaceuticals rose 16.67% to Rs 0.49 crore in the quarter ended June 2024 as
Read more
13 Aug 24
Shukra Pharmaceuticals to discuss results
Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 August 202
Read more
05 Aug 24
Shukra Pharmaceuticals to hold AGM
Shukra Pharmaceuticals announced that the 31th Annual General Meeting (AGM) of the company will be h
Read more
16 Sept 24
Shukra Pharmaceuticals schedules board meeting
Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 September
Read more
24 Sept 24